News | Sutro Biopharma, Inc.

Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones

Nov 10, 2021

- Patient enrollment has been completed for the STRO-002 Phase 1 ovarian cancer dose-expansion cohort, and an interim data update is expected in the second half of 2021 – - STRO-001 Phase 1 dose escalation for non-Hodgkin’s lymphoma and multiple myeloma is ongoing to...

Sutro Biopharma to Participate in Three Upcoming Investor Conferences

Nov 2, 2021

SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma and BioNova Pharmaceuticals Enter into Collaboration for STRO-001 in Greater China

Oct 12, 2021

SOUTH SAN FRANCISCO and SHANGHAI, China, Oct. 12, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create...

Sutro Biopharma Announces Extension of Cytokine Derivative Research Program Under Collaboration with Merck

Sep 30, 2021

SOUTH SAN FRANCISCO, Sept. 30, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 17, 2021

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...

Sutro Biopharma Announces Expansion of Leadership Team

Sep 16, 2021

- Nicole M. Chieffo, MBA, appointed to Vice President of Clinical Operations - Werner Rubas, Ph.D., appointed to Vice President of Preclinical Development SOUTH SAN FRANCISCO, Calif., Sept. 16, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug...

2021 Wells Fargo Virtual Healthcare Conference – Presentation

Sep 9, 2021

Webcast, Sept 9, 2021 at 3:20pm EST

Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

Sep 1, 2021

SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma Announces STRO-002 FDA Fast Track Designation for Patients with Advanced Ovarian Cancer

Aug 18, 2021

SOUTH SAN FRANCISCO, August 18, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...